+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analysis



Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analysis



Cardiovascular Revascularization Medicine 10(3): 195-196




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 063750460

Download citation: RISBibTeXText

DOI: 10.1016/j.carrev.2009.04.010


Related references

Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease Randomized and observational comparisons of secondary prevention trials and their meta-analysis. Journal of the American College of Cardiology 41(6 Supplement A): 526A, March 19, 2003

Additive Benefits of Pravastatin and Aspirin to Decrease Risks of Cardiovascular Disease: Randomized and Observational Comparisons of Secondary Prevention Trials and Their Meta-analyses. Perspectives in Vascular Surgery and Endovascular Therapy 17(1): 65-1-67, 2005

Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses. Archives of Internal Medicine 164(1): 40-44, 2004

Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. American Heart Journal 162(1): 115-24.E2, 2011

Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis. Journal of Internal Medicine 257(5): 399-414, 2005

Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 301(18): 1909-1919, 2009

Aspirin for the Prevention of Cardiovascular Events in Patients With Peripheral Artery Disease: A Meta-analysis of Randomized Trials. Yearbook of Anesthesiology and Pain Management 2010: 9-11, 2010

Low-Dose Aspirin for the Primary Prevention of Cardiovascular Disease in Diabetic Individuals: A Meta-Analysis of Randomized Control Trials and Trial Sequential Analysis. Journal of Clinical Medicine 8(5), 2019

Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials. Cardiovascular Diabetology 16(1): 134, 2018

The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: a meta-analysis of randomized controlled trials. Journal of the Neurological Sciences 332(1-2): 92-96, 2014

Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies. Journal of Thoracic and Cardiovascular Surgery 143(3): 665-675.E4, 2012

Effect of tea on blood pressure for secondary prevention of cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials. Nutrition Reviews 73(4): 236-246, 2015

Legacy Effect of Intensive Blood Glucose Control on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Very High Risk or Secondary Prevention of Cardiovascular Disease: A Meta-analysis of Randomized Controlled Trials. Clinical Therapeutics 40(5): 776-788.E3, 2018

Aspirin in primary prevention of cardiovascular events in women and men (a meta-analysis of randomized controlled trials). Kardiologiia 46(3): 75-76, 2006

Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 295(3): 306-313, 2006